Migraine and High Flow Oxygenotherapy at the Emergency Department (MiOx)

Condition(s) studied

Investigational drug(s) / intervention(s)

oxygenotherapy: High concentration mask delivering 15L/min of oxygen

placebo air aerosol: High concentration mask delivering 15L/min of air

Study summary

Migraine is a common pathology, affecting around 12% of the general population, up to 25% in some cohorts, as well as a significant part of the reasons for emergency room visits.

Unlike cluster headaches, the use of high-flow oxygen therapy has not yet been validated in patients with migraine.

However, several aspects of its pathophysiology, still studied to this day, suggest that the use of normobaric oxygen could have beneficial effects on migraine attacks: tissue hypoxia, cerebrovascular dysfunction with vasodilation, inflammation, etc.

In addition, high-flow oxygen therapy has no significant side effects and almost no contraindication (mainly COPD and other chronic respiratory failure) Its use in the event of a migraine attack would thus allow less recourse to conventional analgesics (with significant side effects for some), a shorter stay in the emergency room, and therefore a benefit in terms of cost and relief for the patient.

In this context, the sponsor wish to carry out a multicenter prospective interventional, single-blind randomized placebo-controlled in parallel groups study.

Eligibility

Primary outcome measure(s)

• Pain evaluation — 30 minutes after aerosol started
  Simple 0-10 pain verbal numerical rating scale (0 being the minimum : no pain, and 10 the maximum : worst pain imaginable by the subject)

Trial sites (1)

More Centre Hospitalier Universitaire de Nice trials in France

Other trials for the same condition